Calcipotriene versus Clobetasol and their Combination in Chronic Plaque Psoriasis A Prospective Cohort Study

Abstract

Background: Topical therapy is the primary treatment for chronic plaque psoriasis. The purpose of the study was to compare the efficacy and safety of Calcipotriene and Clobetasol Propionate (as monotherapy and combination therapy) in participants with chronic plaque psoriasis. newlineMethodology: Study participants were assigned to two trial groups, based on predetermined inclusion and exclusion criteria. In the first trail, participants were assigned to two groups, Group A and Group B. Group A and Group B received a twice-daily topical application of 0.005% Calcipotriene for a duration of 12 weeks, In the second trial, the participants were assigned to two groups, Group C1 and Group C2. Both groups received a topical combination of Calcipotriene (0.005% w/w) as once a day and Clobetasol Propionate (0.05% w/w) as two times a day for 12 weeks. newlineThe efficacy of the treatments was evaluated using two measures: The Psoriasis Area and Severity Index (PASI) and Erythema Scaling, Fissuring, and Induration (ESFI) scores. The safety profile and tolerability of topical treatments were assessed through clinical evaluations of skin safety and discomfort reported by both clinicians and participants. newlineResults: In the first trial groups, both treatments were very effective in lowering PASI and ESFI scores. There was no statistically significant difference between the two groups (pgt0.05). Group A had fewer side effects than Group B. In the second trial group, group C2 had more efficacy than group C1 in reducing PASI and ESFI scores, as the p-value was statistically significant (plt0.05). However, a highly significant difference was seen at 12 weeks with group C2 (plt0.01). But group C1 had fewer side effects than group C2. newlineConclusion: In all trials, Group C2 with twice-daily administration of the tested treatments for twelve weeks demonstrated a quicker clinical and symptomatic recovery than the three study groups who and fewer adverse effects. newline